HOUSTON -- Two commonly used kidney function tests had a large degree of disagreement and were linked with serious health ...

Expert discusses how the prevalence of chronic kidney disease (CKD), as reflected by decreased estimated glomerular ...

Chronic kidney disease (CKD) is a slow health problem that affects how well your kidneys clean your blood. It has five stages ...

Although SGLT2 inhibitors are standard-of-care treatments for CKD, type 2 diabetes, and heart failure (HF), the drugs are underutilized in clinical practice.

In the outpatient setting, the presence of a cystatin C-based estimated glomerular filtration rate (eGFRcys) that is at least ...

The current kidney transplant waitlisting criterion is based on a single measurement of kidney function (estimated glomerular ...

Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

The VISIONARY trial is testing sibeprenlimab, a humanized IgG2 monoclonal antibody, in patients with IgA nephropathy, a population at high risk for kidney failure.

Chronic kidney disease (CKD) was the ninth-leading cause of death worldwide in 2023, accounting for 1.48 million deaths. Its global age-standardized prevalence increased from 3.5% to 14.2%, according ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.